Registry update — unassessed
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS): Randomized, Placebo-controlled Pilot Study.
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Nov 21, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- Without reported outcomes or effect sizes, this abstract does not demonstrate whether metformin is safe, tolerable, or neuroprotective in this population
- Sample size is not reported, making it impossible to assess statistical power or generalizability
- This is a pilot study; findings cannot be generalized to broader populations of older adults with MS
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 9 months
- Population
- Older people with multiple sclerosis (MS)
- Primary outcome
- Safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo
- Effect size
- —
- Significance
- Not reported
- Journal
- State University of New York at Buffalo
- Published
- Nov 21, 2025
Sources
Primary source
- State University of New York at Buffalo ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin.
The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo
How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.